Therapeutic Humanized Anti-CD24 Monoclonal Antibody for Precision Targeted Therapy of Triple-Negative Breast Cancer
Technology Introduction:
Triple-negative breast cancer lacks effective targeted therapies, posing a significant clinical challenge and unmet medical need. HH0146, a first-in-class humanized CD24 mAb developed in Taiwan, holds a Taiwan invention patent and has completed PCT filing. It specifically activates macrophages, promoting cancer cell phagocytosis and reshaping the tumor immune microenvironment. As a novel immune checkpoint inhibitor, HH0146 demonstrates exceptional anti-tumor efficacy.
Industry Applicability:
HH0146, a first-in-class humanized CD24 mAb for triple-negative breast cancer, targets a global market projected to reach $1.5 billion by 2030 (10% CAGR). Its CD24-positive applicability extends to 14 solid cancers, including pancreatic and liver cancer. HH0146 will collaborate with CDMO partners for GMP production to accelerate IND applications. Plans include entering the U.S., China, and EU markets, attracting investment, and advancing Taiwan’s biotech industry.
Currently, there are nine colleges, including the College of Medicine, College of Dentistry, College of Pharmacy, College of Traditional Chinese Medicine, College of Public Health, College of Health Care, College of Life Sciences, College of Humanities and Technology, and College of Medical Engineering, including 23 bachelor's programs, 34 master's programs, 20 doctoral programs, and teaching, research, and medical units such as the Taichung Affiliated Hospital, Beigang Affiliated Hospital, Hsinchu Affiliated Hospital, Children's Hospital, and Tainan Municipal Annan Hospital (commissioned to be built and operated by China Medical University). The university is well-equipped with various research and medical facilities, of which about 70% are related to Chinese and Western medicine. It provides the most complete curriculum in the country with the characteristics of the integration of Chinese and Western medicine, cultivates medical, nursing, pharmaceutical, and technical professionals with the characteristics of the integration of Chinese and Western medicine, and develops the three most Chinese medicine-based fields, including the development of Chinese medicine resources, the research and development of Chinese medicine health foods and anti-disease drugs, and the theory and application of Chinese medicine (including acupuncture). After nearly half a century of intensive cultivation, the university has developed into an excellent institution of higher education in the country and even the world with the most Chinese and Western medicine-based integration characteristics, and has gradually implemented the scientification, modernization, and internationalization of Chinese medicine, as well as pioneered the emerging medicine that combines Chinese and Western medicine.
Name：
Phone：04-2205-3366 #3515
Address：91,Hsueh-Shih Road, Taichung,404, Taiwan,Republic of China
I862019
ITRI-501, an Anti-TIGIT Monoclonal Antibody for Solid Tumor Therapy
Novel Autopilot Jet-Based Electrospinning for Fabricating Functional 3D Scaffolds for Tissue Engineering and Regenerative Medicine Applications
EGFR arginine methylation as a tumor antigen for targeting triple-negative breast cancer
Novel cancer immunotherapeutic agent targeting tumor and tumor immune microenvironment for the treatment of triple negative breast cancer
Technology maturity：Others
Exhibiting purpose：Display of scientific results
Trading preferences：Negotiate by self
*Organization
*Name
*Phone
*Main Purpose
*Discuss Further
*Job Category
*Overall Rating
*Favorite Area
*Key Tech Focus
*Willing to Receive Updates?
Other Suggestions
Coming soon!